Cynata Therapeutics (ASX:CYP) Change In Receivables : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cynata Therapeutics Change In Receivables?

Cynata Therapeutics's change in receivables for the quarter that ended in Dec. 2023 was A$0.00 Mil. It means Cynata Therapeutics's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

Cynata Therapeutics's change in receivables for the fiscal year that ended in Jun. 2023 was A$0.00 Mil. It means Cynata Therapeutics's Accounts Receivable stayed the same from Jun. 2022 to Jun. 2023 .

Cynata Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2023 was A$0.08 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cynata Therapeutics's liquidation value for the six months ended in Dec. 2023 was A$10.04 Mil.

Cynata Therapeutics Change In Receivables Historical Data

The historical data trend for Cynata Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics Change In Receivables Chart

Cynata Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Receivables

Get a 7-Day Free Trial

Cynata Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Cynata Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Cynata Therapeutics (ASX:CYP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cynata Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.077	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Cynata Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Cynata Therapeutics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	11.167	-	1.182	+	0.75 * 0.077	+	0.5 * 0
=	10.04

Cynata Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cynata Therapeutics (ASX:CYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

51S:Germany

Address

100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121

Website

https://www.cynata.com

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics (ASX:CYP) Headlines

No Headlines